

General Shareholders' Meeting
June 19, 2024, at 10:00am

Hôtel Drawing House
21, rue Vercingétorix
75014 Paris

Presentation of nominees for the position of director

Cécile Nguyen-Cluzel



Cécile Nguyen-Cluzel has extensive experience in financial engineering and healthcare private equity. After nearly 30 years investing in French small cap funds (Initiative & Finance, MBO +), Cécile joined the London-based pan-European fund Apposite Capital in January 2024 as Senior Advisor in healthcare for France and Europe. Over the course of her career, she has acquired specific expertise in the growth and buyout of companies (investments of between €10m and €40m) in a variety of healthcare sectors (excluding biotech), such as diagnostics (spin-off of Cerba in 1998), healthcare services (orthoprosthesis, nuclear medicine), CROs and digital health. Cécile has regularly held positions on the strategic committees of her portfolio companies. To date, she is a non-executive Director of an edtech company.

Cécile holds a Master 2 'Ingénierie financière' Dauphine and the certification 'Leading the digital transformation in healthcare' from Harvard medical school.

Marc Dechamps



Marc Dechamps is a biologist with extensive experience in the pharmaceutical industry dating back more than 35 years. During his career, he has worked for corporate pharma companies including GSK & ViiVHealthcare, building his expertise in market development for new products in infectious diseases, immunological disorders, oncology, CNS disorders and vaccines. In 2016, Marc founded and became Managing Director of XMF consulting, a company which supports biotech and biopharma businesses with strategic advice. He has also served as Managing Director of Delphi Genetics (CDMO) and interim CEO of eTheRNA Immunotherapies (mRNA biotech company). Presently, CEO of Bioxodes, a phase 2a clinical stage biotech company (prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients), he serves also as President of the board of InvestSud Tech (group InvestSud) and Board member of HealthTech for Care (HT4C).

Marc is co-academic Director for the advanced masters in biotech & medtech ventures at the Solvay Brussels School of Economics & Management.

Markus Goebel, MD, PhD, MBA



Markus Goebel is a seasoned executive with 30+ year experience in the Life Science industry. Deep understanding and broad hands-on experience across the entire value chain in various Pharma and Bio/Medtech positions incl. as a board member. Managing Director Novartis Venture Fund (2004-2019) in the US&EU with top quartile track record. Founder & CEO of M&G Advisors GmbH (Bio-and Medtech consulting with a focus to fundraising and transactions).

MBA finished with dissertation on innovation in the Pharma industry to characterize blockbuster drugs.

Certified MD in Oncology/Hematology (plus additional certifications) with more than 10 years in academia.

Martine George, MD



Martine George, MD, has a rich Pharma and Academic international expertise mainly in the US. She is a proven leader of large development teams for global Fortune 500 pharmaceutical organizations and small biotechnology companies. She was Principal, Senior Executive consultant, Life Sciences in Global Development Associates, Inc., Skillman, NJ, key contributor to strategies leading to multiple drug regulatory approvals or licensing/acquisitions and significant M&A. She was Vice President, Global Medical Affairs, Oncology, at Pfizer Inc., New York, NY, driving the global medical strategy and worldwide medical affairs and reimbursement activities for oncology drugs. Previously Senior Vice President, Drug Development and Chief Medical Officer at GPC Biotech Inc., Princeton; Senior Vice President, Head of Oncology at Johnson & Johnson, Raritan, NJ; Vice President, Medical Affairs at Rhone-Poulenc Rorer (Sanofi-Aventis), Collegeville, PA. She began her carrier at Sandoz Pharmaceuticals Corporation (Novartis), East Hanover, NJ, and previously at American Cyanamid Pearl River, NY. She has a strong expertise in clinical research, medical affairs, and regulatory affairs specializing in oncology and other therapeutic areas. Her extensive Board experiences were also acquired in large and small companies; in public and private (i.e Phaxiam/ Erythech/ GammaMabs/ Cytomics, Inc/ Non-for-profit organizations Breast Cancer Research Foundation, New York, NY/Resource Center for Women & Their Families, Hillsborough, NJ).

Her experience includes Memorial Sloan Kettering Cancer Center, New York, Visiting Professor / Institut Gustave Roussy Villejuif, France Service Chief, Gynecological Outpatient Clinic, Chairman, French Comprehensive Cancer Centers' Gynecological Group Secretary, EORT Gynecological Cancer Cooperative Group.
